Efficacy and Safety of RBX2660 for the Prevention of Recurrent Clostridium difficile
Infection: Results of the PUNCH CD 2 Trial

Erik R. Dubberke, MD, MSPH; Christine Lee, MD; Robert Orenstein, DO and Sahil Khanna, MBBS, MS; Gail Hecht, MD; Joseph Fraiz, MD

efficacy and safety of rbx2660 to prevent recurrent clostridium difficile poster image

Download this poster (220 KB)
Download the abstract (16 KB)

Infectious Diseases Week (ID Week)
October 26-30, 2016, New Orleans, LA


  • Experience indicates microbiota-based therapies are highly efficacious at preventing Clostridium difficile (CDI) recurrences.
  • There is a need for high-quality data on efficacy and safety.
  • The PUNCH CD 2 trial was a randomized, placebo-controlled, double-blinded study to assess the safety and efficacy of RBX2660, a microbiota-based drug targeted at recurrent CDI.


  • Patients with recurrent CDI were randomized to: 2 doses of RBX2660 (Group A); 2 doses of placebo (Group B); or 1 dose of RBX2660 and 1 dose of placebo (Group C) via enema with doses 7 days apart.
  • Control of CDI symptoms with antibiotics was required prior to enrollment. Antibiotics were discontinued 24-48 hours prior to the first enema.
  • Failures could receive up to 2 doses of open-label active treatment, 7 days apart, Figure 1.
  • Safety was assessed via a patient diary: in clinic at 1, 4, and 8 weeks and via telephone at 2, 3 and 5-7 weeks and at 3, 6, 12 and 24 months. Durability was assessed concurrently and is on-going until 24 months.


  • Assess dosing strategy for RBX2660
    • Efficacy of 1 vs. 2 doses; timing of doses
  • Long-term safety of RBX2660

Major Inclusion Criteria

  • Age ≥ 18 years old
  • A positive stool test for Clostridium difficile within 60 days prior to enrollment
  • At least two recurrences of CDI after a primary episode
  • At least two episodes of severe CDI resulting in hospitalization

Major Exclusion Criteria

  • History of inflammatory bowel disease (ulcerative colitis, Crohn’s disease or microscopic colitis); irritable bowel syndrome; chronic diarrhea; celiac disease
  • Colostomy
  • Evidence of active colitis
  • Known exposure to antibiotics within 6 months after study enrollment
  • Compromised immune system
  • White blood cell count <1000 cells/μL


  • Microbiota-based drug manufactured from live human-derived microbes using standardized processes and controls.
  • Each unit of RBX2660 is identified by a unique batch number and is traceable to a specific donor and recipient.

Definition of Success

  • The absence of CDI associated diarrhea -without the need for retreatment with a Clostridium difficile anti-infective therapy or fecal transplant through 8 weeks after administration of the second dose of the assigned treatment in the blinded phase.

Definition of Failure (All 4 Criteria Required)

  • Presence of diarrhea, with or without other CDI symptoms, at <8 weeks after last treatment
  • A positive stool test for Clostridium difficile
  • Need for retreatment for CDI
  • No other cause for diarrhea identified


  • A total of 127 patients at 21 sites in the U.S. and Canada were enrolled between December 10, 2014 through November 13, 2015 were included in the intent-to-treat analysis:
    • Group A (2 doses of RBX2660): n=41
    • Group B (2 doses of placebo): n=44
    • Group C (1 dose of RBX2660 and 1 dose of placebo: n=42
  • The median age was: 63.0, range: 18-92 years; sex: 62% female; median prior CDI episodes (4 range: 2-14), Table 1.



  • Group C (1 dose) was superior to Group B (placebo): 66.7%, 28/42 vs. 45.5%, 20/44, P=0.048.
  • There was no difference between Group A: 2 doses (61%, 25/41) vs. Group C: 1 dose (66.7%), P=0.589.
  • The combined success in Groups A and C (1 or 2 doses) was superior to Group B: placebo, 63.9% vs. 45.5%, P=0.046.


  • Of patients in groups A and C who went on to receive open-label treatment, 70% succeeded (21/30).
  • All 24 patients who failed placebo (experienced recurrence) went on to receive open-label treatment with RBX2660. Of these patients, 87.5% (21/24) were successful when treated with RBX2660.


  • For all patients who were randomized to receive at least 1 active treatment (Groups A and C), the overall success (blinded and open-label) was 89.2% (n=74/83) compared with a 45.5% (20/44) placebo response, P < 0.0001, Figure 2.


  • There were 580 adverse events (AEs) reported in 94 patients and 45 serious AEs in 26 patients with a mean follow-up of 8.3 months, Table 2.
  • AEs were primarily gastrointestinal (n=242, 41.7%).
  • There were no unanticipated AEs and there was no significant difference in proportion of AEs or serious AEs among the treatment groups.


  • Of the patients who received at least 1 active treatment and were successful, the long-term CDI-free rate (median follow-up: 8.3 months; range: 1.6 to 14.9 months) was 95.8%.
  • Of these patients, 4.2% developed a new episode of CDI confirmed by a positive test > 8 weeks after that last RBX2660 treatment.
  • One recurrence occurred after antibiotics for a dog bite and one during a hospital stay for small bowel obstruction. Reasons were unknown for 2 cases.


  • RBX2660 administered via enema is a safe and effective and effective treatment for recurrent CDI.
  • Overall efficacy of RBX2660 was 89.2% in a randomized, double-blinded, placebo-controlled study in patients with recurrent CDI.
  • AEs were primarily gastrointestinal; there were no unanticipated AEs.
  • RBX2660 provided a durable cure.
  • The results were consistent with those achieved in the open-label PUNCH CD trial.1


    Orenstein R, Dubberke E, Hardi R, et al. Safety and durability of RBX2660 (microbiota suspension) for recurrent Clostridium difficile infection: results of the PUNCH CD study. Clin Infect Dis. 2016;62:596-602.